Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

8-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 57121282.  A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 57121282.  The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY) and a New Drug Application (NDA) has been accepted for Priority Review by the FDA.  The hepatology portfolio includes the HCV protease inhibitor compound RG7227 (ITMN-191) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program.  For additional information about InterMune and its R&D pipeline, please visit

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... MURRAY HILL and NEW PROVIDENCE, ... management and engineering professionals are invited to meet with ... Conference and Technical Exhibition to be held at McCormick ... August 3-6. "Hospitals demand nothing less ... said Mark Sanda , Linde,s Healthcare Segment manager. ...
(Date:7/28/2014)... July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, August ... www.isispharm.com How:Live on the Internet. Simply log onto ... participate during the live event, a replay of the ... www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, INC. ...
(Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
Breaking Medicine Technology:Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7
... , , ... use of stem cells in the treatment of heart failure, ... physicians have performed the world,s first phase-one FDA-approved clinical trial ... The clinical trial is being conducted by a team of ...
... , SAN MATEO, Calif., July 24 ... the preliminary results of a short-term clinical study (Study ... following pretreatment with an FDA-approved topical anesthetic. As part ... U.S. Food and Drug Administration (FDA) requested the study ...
Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4
(Date:7/28/2014)... Top Northridge dentist , Dr. Farshid Ariz, is ... new dentist can be an intimidating experience. Many people struggle ... and worry about how they will connect with a new ... concerns and dental needs and works to ensure that each ... special coupon can help patients get the treatments they need ...
(Date:7/28/2014)... Freeonlinelifeinsuranceleads.com has released a new blog ... insurance quotes. , Comparing life insurance quotes can help ... costs. Finding affordable coverage is easier online by visiting ... agencies and displays them on a single web page. ... find cheaper coverage, but they can also learn more ...
(Date:7/28/2014)... (HealthDay News) -- Following a healthy lifestyle may help ... issues, a new study indicates. Researchers suggested that ... should be educated about how their diet ... future. "These findings are important because they indicate ... have the opportunity to influence their own health outcomes," ...
(Date:7/28/2014)... Nevada (PRWEB) July 28, 2014 Mahendra ... Trivedi, hosted the Trivedi Online Workshop ‘Consciousness is Power’ ... PM (EST). During this workshop, participants from all over ... importance of making a deeper connection to their inner ... the participants explored the various advantages of raising consciousness ...
(Date:7/28/2014)... 28, 2014 Alta Resources , ... (BPO) for Fortune 500 brands, announced today that it ... locations in Wisconsin, California, Florida and the Philippines. More ... its Fort Myers campus, and the company announced that ... is to support several health-insurance clients, which have seasonal ...
Breaking Medicine News(10 mins):Health News:Northridge Dentist, Dr. Farshid Ariz, is Now Offering a $100 Coupon for New Patients 2Health News:Comparing Life Insurance Quotes Online Offers 3 Important Advantages! 2Health News:Healthy Habits May Help Childhood Cancer Survivors Avoid Chronic Ills 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 2Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 4
... Hospitals (UH) Case Medical Center is conducting the first ... "heat therapy" or local radiofrequency energy to treat premature ... to the energy produced by radio waves directed with ... a nerve. Premature ejaculation (PE) affects 20 percent ...
... Research Institute (LRI) today announced the award of 12 ... drive innovation and discover novel approaches to understand and ... diseases lupus. Awarded for the highest-ranked ... topics and multi-disciplinary approaches that mirror the heterogeneity and ...
... Institute (GHI) and Inserm (Institut National de la Sant ... for biomedical research) has discovered that a class of ... in cancer cells also kills the parasite that causes ... new strategy for combating this deadly disease. The ...
... leg ulcers is good quality nursing care and the ... University of Leeds has shown that ultrasound therapy does nothing ... contrary to what had been expected. Traditional methods of nursing ... as well, the authors conclude. "The ,healing energy, of ...
... might be required for maximum anti-tumor activity when ... studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The ... Proceedings of the National Academy of Sciences ... HER3 receptor limits the effectiveness of two classes ...
... An analysis conducted by Ohio State University cancer ... to the treatment of patients with advanced ovarian cancer ... value of various clinical strategies will be published online ... , The researchers performed a cost-effectiveness analysis looking at ...
Cached Medicine News:Health News:University Hospitals Case Medical Center testing innovative 'heat therapy' for premature ejaculation 2Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 2Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 3Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 4Health News:Malaria's weakest link 2Health News:Laughter really is the best medicine (for leg ulcers) 2Health News:Hit multiple targets for maximum benefit in HER2-positive breast cancer, studies suggest 2Health News:Ohio State study: Targeted ovarian cancer therapy not cost-effective 2Health News:Ohio State study: Targeted ovarian cancer therapy not cost-effective 3
The ABL77 is always ready to use. No manual cassette preparation or calibration necessary prior to testing. Portable with battery. For both high and low volume testing....
348 is fully automated blood gas systems offering a cost-effective solution for critical care testing in settings with low to medium workloads....
The AVL Omni modular system is a complete blood gas solution designed for high-volume critical care use, with customized test combinations, minimum intervention and flexibility....
... optimal combination of performance and rapid, ... mL swinging bucket rotor. DiscoveryTMM120 SE ... to 8.3 ml, with a small ... quiet operation, rotor imbalance detection, thermo-electric ...
Medicine Products: